| Literature DB >> 25606463 |
Kammara Rajagopal1, Praveen Kumar Singh2, Rajesh Kumar2, Kaneez Fatima Siddiqui2.
Abstract
An efficient and reproducible method for transformation depends on the competency of the organism. We have developed a simple method for the preparation of competent Escherichia coli, Kluyveromyces lactis, and Bifidobacterium sp. by using a buffer containing cetyl trimethyl ammonium bromide (CTAB) and permits efficient uptake of plasmid DNA and ligation-reaction products. Cells are harvested, washed, mixed with 1-10 μg/ml CTAB, incubated, and followed by a buffer wash. For long-term storage of competent cells, bacteria may be frozen in 10% glycerol without the addition of other components. The transformation process is very simple; plasmid DNA and the cells are mixed and incubated for 5-60 min at 4 °C; no heat pulse is required, and the duration of incubation at 4 °C is not crucial.Entities:
Keywords: CTAB; CaCl2 method; Competency; FACS; TSS method of transformation; Transformation
Year: 2014 PMID: 25606463 PMCID: PMC4287956 DOI: 10.1016/j.mgene.2014.10.002
Source DB: PubMed Journal: Meta Gene ISSN: 2214-5400
Strains and plasmids used in this study.
| Bacterial strain | Source | Reference |
|---|---|---|
| Fecal isolate | This study | |
| DSM 20213 | This study | |
| DSM20215 | This study | |
| DSM20089 | This study | |
| NEB C2987 H, P9751 | This study | |
| XL1blue | Commercial source | This study |
| Commercial source | This study | |
| MTCC7049 | This study | |
| Commercial source | This study | |
| Plasmids | Description | Reference |
| pET23(d) | T7 promoterbased/Novagen | Novagen |
| pETXFP | xfp gene cloned in pET23(d) | This study |
| pTraj1 | Bifidobacterial expression plasmid | This study |
| pTraj2 | Bifidobacterial expression plasmid | This study |
| p | Commercial source | This study |
B. refers to Bifidobacterium.
Indigenous bifidobacterial expression plasmids.
Effect of different conc. of CTAB on transformation efficiency.
| Serial No. | Conc. of CTAB | Transformation efficiency | Lysis of cells | Growth of cells |
|---|---|---|---|---|
| A | 10 | – 0 – | Yes | Exponential phase |
| 5 | – 0 – | Yes | Exponential phase | |
| 1 | 4.1 ± 0.18 × 109 | Partial | Exponential phase | |
| B | 10 | 1.10 ± 0.17 × 105 | 10–20% | Exponential phase |
| 5 | 4.10 ± 0.09 × 104 | No | Exponential phase | |
| 1 | 3.8 ± 0.10 × 105 | No | Exponential phase | |
| C | 10 | 1.30 ± 0.08 × 108 | Less than 1% | Exponential phase |
| 5 | 2.40 ± 0.09 × 108 | No | Exponential phase | |
| 1 | 3.1 ± 0.10 × 108 | No | Exponential phase |
A. E. coli (DH5α, XL1blue, BL21DE3) JM109, B. B. catenulatum, and C. K. lactis cells were incubated for 15 min in CTAB for all the above methods.
Mean ± SEM of triplicate plates.
Effect of different concentrations of CTAB on E. coli and B. catenulatum cell wall integrity and viability.
| Cells | 0 time (no. of cell) | 10 minute incubation (no. of cells) | Reduction in viability after 10 minute incubation (%) |
|---|---|---|---|
| 11 × 109 | 12 × 109 | 0 | |
| 11 × 109 | 9.4 × 109 | 14.1 | |
| 11 × 109 | 11.004 × 109 | 8.18 | |
| 11 × 109 | 11 × 109 | 0 | |
| 11 × 109 | 11.2 × 109 | 0 | |
| 11 × 109 | 10.24 × 109 | 6.90 | |
| 11 × 109 | 10.86 × 109 | 1.2 | |
| 11 × 109 | 11 × 109 | 0 | |
| 11 × 109 | 10.89 × 109 | 1 | |
| 11 × 109 | 11 × 109 | 0 |
Transformation efficiency of various organisms.
| Strain | Transformation efficiency |
|---|---|
| A. XL1blue | 5.1 ± 0.16 × 109 |
| DH5α | 4.8 ± 0.18 × 109 |
| BL21DE3 | 5.8 ± 0.16 × 109 |
| JM109 | 4.5 ± 0.11 × 109 |
| B. | 3.2 ± 0.19 × 105 |
| | 2.9 ± 0.17 × 105 |
| C. | 3.1 ± 0.12 × 107 |
| D. XL1blue | 4.9 ± 0.12 × 107 |
| E. XL1blue | 2.5 ± 0.1 × 109 |
All the above cells were subjected to electroporation/Gene pulsing. A represents E. coli strains, B corresponds to bifidobacterial strains, C corresponds to yeasts, and D represents XL1blue competent cells made through TSS method of Chung et al. (1989) (− ve control). E represents cells treated with CaCl2 control experiment for comparison. For A and B samples 1 μg, and for sample C 10 μg of CTAB have been used. B. breve, B. bifidum, and B. asteroids were also used but not represented as the efficiency was not encouraging.
Strains and plasmids used in this study.
| Bacterial strain | Strain no. | Reference |
|---|---|---|
| Fecal isolate | This study | |
| NEB C2987 H | This study | |
| XL1blue | Stratagene | This study |
| BL21DE3 | Novagen | This study |
| MTCC | This study | |
| NEB | This study | |
| Plasmids | Reference | |
| p | Novagen | |
| p | This study | |
| p | This study | |
| p | This study | |
B. refers to Bifidobacterium.
Fig. 1A, B, and C. Fluorescence micrographs of CTAB treated recombinant E. coli subjected to PI staining. Microscopy was used to investigate cell membrane damage and viability. Phase contrast (1000 ×) and fluorescence microscopy photos of E. coli. These images illustrate the cells and some granules take up nuclear stain. A: Cells treated with 10 μg/ml CTAB followed by PI staining (20 μl/ml), they were further washed to remove the excessive stain. Same cells were subjected to fluorescence microscopy. B: Cells treated with 5 μg/ml CTAB followed by PI staining, they were further washed to remove excess stain. C: Cells treated with 1 μg/ml CTAB followed by PI similar procedure as above was followed. Note: left row shows original (cells in black and white), and right row shows overlaid. The arrows indicate PI labeled cells.
Fig. 2FACS analysis of the cells treated with different concentrations of CTAB (1 to 10 μg) subsequently they were subjected to PI staining. The PI stained cells were subjected to FACS to capture only the PI stained cells. (A) Control cells not treated with CTAB but treated with PI only, (B) cells treated with 1 μg of CTAB followed by PI staining, (C) cells treated with 5 μg of CTAB followed by PI staining, and (D) cells treated with 10 μg of CTAB followed by PI staining. Fluorescence data: FL1, 525 emissions: FL3, 620 nm emission. Inlet picture signifies extent of fluorescence.
Fig. 3A. Cells were subjected to CTAB treatment followed by PMA and were screened for plasmid DNA. The same cells were further subjected to heat treatment and centrifugation. The resultant supernatant was used as a template for amplification of full-length and partial 16S rRNA and f6ppk. Isolated plasmid DNA and complete, partial and full-length f6ppk were amplified and subjected to 1% Agarose gel electrophoresis. Lane 1: Amplification of full-length 16S rRNA from control cells; not treated with CTAB and PMA. Lane 2: Amplification of full-length 16S rRNA from E. coli treated with CTAB and PMA (1 μg). Lane 3: Amplification of 16S rRNA from Bifidobacterium treated with CTAB and PMA (5 μg). Lane 4: Amplification of 16S rRNA from E. coli treated with 10 μg/ml CTAB and PMA. Lane 5: Molecular weight markers for 100 (not seen in the gel picture), 300, 500, 750, 1000, 1500, 2000, 3000 and 5000 bp. Lane 6: Amplification of 16S rRNA from Bifidobacterium treated with 10 μg/ml CTAB and PMA. Lane 7: Amplification of full-length f6ppk from Bifidobacterium treated with 5 μg/ml CTAB and PMA. Lane 8: Amplification of partial 16S rRNA from control E. coli (un-treated with CTAB and PMA). Lane 9: Amplification of partial 16S rRNA from E. coli treated with 5 μg/ml CTAB and PMA. Lane 10: Amplification of partial 16S rRNA from Bifidobacterium treated with 5 μg/ml CTAB and PMA. B. Cells were subjected to CTAB treatment followed by PMA and were screened for plasmid DNA and PCR amplified. The same cells were further subjected to heat treatment and centrifugation. The resultant supernatant was used as a template for amplification of full-length and partial f6ppk and purification of plasmid DNA. Isolated plasmid DNA and complete, partial and full-length f6ppk were amplified and subjected to 1% Agarose gel electrophoresis. Lane 1: Plasmid DNA isolated from control E. coli. Lanes 2 and 3: Plasmid DNA isolated from E. coli and yeasts treated with 1 and 10 μg/ml CTAB. Lane 4: Plasmid DNA isolated from E. coli treated with 10 μg/ml CTAB. Lane 5: Molecular weight markers for 1, 1.5, 2.0, 2.5, 3.0, 4.0, 5.0, 6.0, 7.0, 8.0 and 9.0 kbp. Lane 6: PCR amplification of f6ppk from control E. coli cells. Lane 7: PCR amplification of f6ppk treated with 10 μg/ml CTAB (E. coli). Lanes 8 and 9: PCR amplification of f6ppk from yeasts and E. coli treated with 1 or 10 μg/ml CTAB.